Bro wn FD, Johns LM, Mullan S. Dimethyl sulfoxide in experimental brain injury, with 
comparison to mannitol. J Neurosurg . July 1980;53(1):58–62. 78. Bro wn FD, Johns L, Mullan S. Dimethyl sulfoxide therapy following penetrating brain 
injury. Ann NY Acad Sci . 1983;411:245–252. 79. Carlson KK. (ed.) AACN Advanced Critical Care Nursing . Elsevier Saunders, St Louis, 
MO, 2009; p. 554. 80. Campbell WW . DeJong’s the Neurologic Examination , 6th edn. Lippincott Williams & 
Wilkins, Philadelphia, PA, 2005. 81. W aller FT, Tanabe CT, Paxton HD. Treatment of elevated intracranial pressure with 
dimethyl sulfoxide. Ann NY Acad Sci . 1983;411:286–292. 82. Marshall LF , Camp PE, Bowers SA. Dimethyl sulfoxide for the treatment of intracranial 
hypertension: A preliminary trial. Neurosurgery . June 1984;14(6):659–663. 83. Gumerlock MK, Neuwelt EA. Treating intracranial pressure with dimethyl sulfoxide. J Neurosurg . 1984;14:662–663.235 DMSO in Clinical Neuroprotection
 84. Camp PE, James HE, Werner R. Acute dimethyl sulfoxide therapy in experimental brain 
edema: Part I. Effects on intracranial pressure, blood pressure, central venous pressure, 
and brain water and electrolyte content. Neurosurgery . 1981;9:28–33. 85. Del Bigio M, James HE, Camp PE, Werner R, Marshall L, Tung H. Acute dimethyl 
sulfoxide therapy in brain edema. Part 3: Effect of a 3-hour infusion. Neurosurgery . 1982;10:86–89. 86. Tsuruda J, James HE, Camp PE, Werner R. Acute dimethyl sulfoxide therapy in experi -
mental brain edema: Part 2. Effect of dose and concentration on intracranial pressure, blood pressure, and central venous pressure. Neurosurgery . 1982;10:355–359. 87. Karaça M, Bilgin UY , Akar M, de la Torre JC. Dimethyl sulphoxide lowers ICP after 
closed head trauma. Eur J Clin Pharmacol . 1991;40:113–114. 88. K ulah A, Akar M, Baykut L. Dimethyl sulfoxide in the management of patient with 
brain swelling and increased intracranial pressure after severe closed head injury. Neurochirurgia (Stuttg ). 1990;33:177–180. 89. Chamoun R, Robertson CS, Gopinath SP . Outcome in patients with blunt head 
trauma and a Glasgow Coma Scale score of 3 at presentation. J Neurosurg . October 
2009;111(4):683–687. doi: 10.3171/2009.2.JNS08817. 90. Leitgeb J, Mauritz W, Brazinova A, Majdan M, Janciak I, Wilbacher I, Rusnak M. 
Glasgow Coma Scale score at intensive care unit discharge predicts the 1-year out -
come of patients with severe traumatic brain injury. Eur J Trauma Emerg Surg . June 
2013;39(3):285–292. 91. Rosenfeld JV , Maas AI, Bragge P, Morganti-Kossman M, Manley G, Gruen R. Early 
management of severe traumatic brain injury. Lancet. 2012;380:1088–1098. 92. Chen Y , Chan PH, Swanson RA. Astrocytes overexpressing Cu, Zn superoxide dis -
mutase have increased resistance to oxidative injury. Glia. 2001;33:343−347. 93. Seki Y , Feustel PJ, Keller RW, Tranmer BI, Kimelberg HK. Inhibition of ischemia-
induced glutamate release in rat striatum by dihydrokinate and an anion channel blocker. Stroke. 1999;30:433−440. 94. Rossi DJ, Oshima T, Attwell D. Glutamate release in severe brain ischemia is mainly by 
reversed uptake. Nature . 2000;403:316−321. 95. W eber JT. Altered calcium signaling following traumatic brain injury. Front Pharmacol . 2012;3:60. 96. Y i JH, Hazell AS. Excitotoxic mechanisms and the role of astrocytic glutamate trans -
porters in traumatic brain injury. Neurochem Int. 2006;48:394–403. 97. Bullock R, Zauner A, Woodward J, Myseros J, Choi S, Ward JD, Marmarou A, Young 
HF. Factors affecting excitatory amino acid release following severe human head injury. J Neurosurg . 1998;89:507–518. 98. Camici GG, Stef fel J, Akhmedov A, Schafer N, Baldinger J, Schulz U, Shojaati K. 
Dimethyl sulfoxide inhibits tissue factor expression, thrombus formation, and vascular smooth muscle cell activation: A potential treatment strategy for drug-eluting stents. Circulation . 2006;114:1512–1521. 99. Hulsmann S, Greiner C, K ohling R. Dimethyl sulfoxide increases latency of anoxic termi -
nal negativity in hippocampal slices of guinea pig in vitro. Neurosci Lett . 1999;261:1–4. 100. Ginsb urg K, Narahashi T. Time course and temperature dependence of allethrin modu -
lation of sodium channels in rat dorsal root ganglion cells. Brain Res . 1999;847:38–49. 101. Lu C, Mattson MP . Dimethyl sulfoxide suppresses NMDA- and AMPA-induced ion 
currents and calcium influx and protects against excitotoxic death in hippocampal neu -
rons. Exp Neurol . 2001;170:180–185. 101a. Wright D W, Yeatts SD, Silbergleit R, Palesch YY , Hertzberg VS, Frankel M, 
Goldstein FC, Caveney AF, Howlett-Smith H, Bengelink EM, Manley GT, Merck LH, 
Janis LS, Barsan WG; the NETT Investigators. Very early administration of progester -
one for acute traumatic brain injury. N Engl J Med . 2014;371:2457–2466.236 Dimethyl Sulfoxide (DMSO) in Trauma and Disease
 101b. Sk olnick BE, Maas AI, Narayan RK, van der Hoop RG, MacAllister T, Ward JD, 
Nelson NR, Stocchetti N; the SYNAPSE Trial Investigators. A clinical trial of proges -
terone for severe traumatic brain injury. N Engl J Med . 2014;371:2467–2476. 102. Mayer CL, Huber BR, Peskind E. Traumatic brain injury, neuroinflammation, and post-
traumatic headaches. Headache . October 2013;53(9):1523–1530. 103. Hsieh CL, Kim CC, Ryba BE, Niemi EC, Bando JK, Locksle y RM, Liu J, Nakamura 
MC, Seaman WE. Traumatic brain injury induces macrophage subsets in the brain. Eur J Immunol . August 2013;43(8):2010–2022. 104. Lin Y , Wen L. Inflammatory response following diffuse axonal injury. Int J Med Sci . 2013;10(5):515–521. 105. Hollebeeck S, Raas T, Piront N, Schneider YJ, Toussaint O, Larondelle Y , During A. 
Dimethyl sulfoxide (DMSO) attenuates the inflammatory response in the in vitro intes -
tinal Caco-2 cell model. Toxicol Lett . 2011;206:268–275. 106. Dinarello CA. A clinical perspective of IL-1 β as the gatekeeper of inflammation. Eur J Immunol . May 2011;41(5):1203–1217. 107. Dinarello CA. Interleukin-1 in the pathogenesis and treatment of inflammatory dis -
eases. Blood . April 7, 2011;117(14):3720–3732. 108. Scheller J, Chalaris A, Schmidt-Arras D. The pro- and anti-inflammatory properties of 
the cytokine interleukin-6. Biochim Biophys Acta . 2011;1813:878–888. 109. Ja wa RS, Anillo S, Huntoon K. Interleukin-6 in surgery, trauma, and critical care part II: 
Clinical implications. J Intensive Care Med. 2011;26:73–87. 110. Manto vani A, Sica A, Sozzani S, Allavena P, Vecchi A, Locati M. The chemokine 
system in diverse forms of macrophage activation and polarization. Trends Immunol . 2004;25:677–686. 111. Mak CH, Lu YY , Wong GK. Review and recommendations on management of refrac -
tory raised intracranial pressure in aneurysmal subarachnoid hemorrhage. Vasc Health 
Risk Manage . 2013;9:353–359. 112. Pierot L, Wakhloo AK. Endovascular treatment of intracranial aneurysms: Current sta -
tus. Stroke. July 2013;44(7):2046–2054. 113. Mullan S, Jafar J, Hanlon K, Brown F. Dimethyl sulfoxide in the management of postop -
erative hemiplegia. In Arterial Spasm , ed. R.H. Wikins. William & Wilkins, Baltimore, 
MD, 1980; pp. 646–653. 114. Roof RL, Duvde vani R, Heyburn JW, Stein DG. Progesterone rapidly decreases 
brain edema: Treatment delayed up to 24 hours is still effective. Exp Neurol . April 
1996;138(2):246–251. 115. Stein DG. Progesterone e xerts neuroprotective effects after brain injury. Brain Res Rev . March 2008;57(2):386–397. 116. García-Estrada J, Luquín S, Fernández AM, Garcia-Segura LM. Dehydroepiandrosterone, 
pregnenolone and sex steroids down-regulate reactive astroglia in the male rat brain 
after a penetrating brain injury. Int J Dev Neurosci . April 1999;17(2):145–151. 117. O’Connor CA, Cernak I, Johnson F , Vink R. Effects of progesterone on neurologic and 
morphologic outcome following diffuse traumatic brain injury in rats. Exp Neurol . May 
2007;205(1):145–153. 118. Thomas AJ, Nockels RP, Pan HQ, Shaffrey CI, Chopp M. Progesterone is neuro -
protective after acute experimental spinal cord trauma in rats. Spine. October 15, 
1999;24(20):2134–2138. 119. Chen J, Chopp M, Li Y . Neuroprotective effects of progesterone after transient middle 
cerebral artery occlusion in rat. J Neurol Sci . December 1, 1999;171(1):24–30. 120. K umon Y , Kim SC, Tompkins P, Stevens A, Sakaki S, Loftus CM. Neuroprotective 
effect of postischemic administration of progesterone in spontaneously hypertensive 
rats with focal cerebral ischemia. J Neurosurg . May 2000;92(5):848–852.237 DMSO in Clinical Neuroprotection
 121. Jiang N, Chopp M, Stein D, Feit H. Progesterone is neuroprotecti ve after transient mid -
dle cerebral artery occlusion in male rats. Brain Res . 1996;735:101–107. 122. Jiang N, K owaluk EA, Lee CH, Mazdiyasni H, Chopp M. Adenosine kinase inhibition 
protects brain against transient focal ischemia in rats. Eur J Pharmacol . February 12, 
1997;320(2–3):131–137. 123. Wright D W, Kellermann AL, Hertzberg VS, Clark PL, Frankel M, Goldstein FC. ProTECT: A randomized clinical trial of progesterone for acute traumatic brain injury. Ann Emerg Med . 2007;49:391–402. 124. Deutsch ER, Espinoza TR, Atif F, Woodall E, Kaylor J, Wright DW. Progesterone’s 
role in neuroprotection, a review of the evidence. Brain Res . September 12, 
2013;1530:82–105. 125. Xiao GM, Wei J, Wu ZH. Clinical study on the therapeutic effects and mechanism of 
progesterone in the treatment for acute severe head injury. Zhonghua Wai Ke Za Zhi . 2007;45(2):106–108. 126. W ei J, Xiao GM. The neuroprotective effects of progesterone on traumatic brain injury: 
current status and future prospects. Acta Pharmacol Sin . 2013;34(12):1485–1490. 127. Shear D A, Galani R, Hoffman SW, Stein DG. Progesterone protects against necrotic 
damage and behavioral abnormalities caused by traumatic brain injury. Exp Neurol . November 2002;178(1):59–67. 128. Mang at HS. Severe traumatic brain injury. Continuum  (Minneap Minn ). June 
2012;18(3):532–546. 129. McCone ghy KW, Hatton J, Hughes L, Cook AM. A review of neuroprotection pharma -
cology and therapies in patients with acute traumatic brain injury. CNS Drugs . July 1, 
2012;26(7):613–636. 130. Jae ger M, Dengl M, Meixensberger J, Schuhmann MU. Effects of cerebrovascular pres -
sure reactivity-guided optimization of cerebral perfusion pressure on brain tissue oxy-
genation after traumatic brain injury. Crit Care Med . 2010;3:1343–1347. 131. Menon DK, Coles JP, Gupta AK, Fryer TD, Smielewski P, Chatfield DA, Aigbirhio F, 
Skepper JN, Minhas PS, Hutchinson PJ. Diffusion limited oxygen delivery following 
head injury. Crit Care Med . 2004;3:1384–1390. 132. Oddo M, Le vine JM, Mackenzie L, Frangos S, Feihl F, Kasner SE, Katsnelson M, 
Pukenas B, Macmurtrie E, Maloney-Wilensky E. Brain hypoxia is associated with short-term outcome after severe traumatic brain injury independently of intracranial hypertension and low cerebral perfusion pressure. Neurosurgery . 2011;3:1037–1045. 133. Glenn TC, Kelly DF, Boscardin WJ, McArthur DL, Vespa P, Oertel M, Hovda DA, 
Bergsneider M, Hillered L, Martin NA. Energy dysfunction as a predictor of outcome after moderate or severe head injury: Indices of oxygen, glucose, and lactate metabo -
lism. J Cereb Blood Flow Metab . 2003;3:1239–1250. 134. Unterber g AW, Stover J, Kress B, Kiening KL. Edema and brain trauma. Neuroscience . 2004;129(4):1021–1029. 135. Bor -Seng-Shu E, Kita WS, Figueiredo EG, Paiva WS, Fonoff ET, Teixeira MJ, Panerai 
RB. Cerebral hemodynamics: Concepts of clinical importance. Arq Neuropsiquiatr . May 2012;70(5):352–356. 136. Jacob SW , de la Torre JC. Pharmacology of dimethyl sulfoxide in cardiac and CNS 
damage. Pharmacol Rep . March–April 2009;61(2):225–235. 137. Jia Z, Zhu H, Li Y , Misra HP. Potent inhibition of peroxynitrite-induced DNA strand 
breakage and hydroxyl radical formation by dimethyl sulfoxide at very low concentra -
tions. Exp Biol Med  (Maywood). May 2010;235(5):614–622. 138. Sanmartín-Suárez C, Soto-Otero R, Sánchez-Sellero I, Méndez-Álv arez E. Antioxidant 
properties of dimethyl sulfoxide and its viability as a solvent in the evaluation of neuro -
protective antioxidants. J Pharmacol Toxicol Methods . 2011;63(2):209–215.238 Dimethyl Sulfoxide (DMSO) in Trauma and Disease
 139. Stein DG. Is progesterone a w orthy candidate as a novel therapy for traumatic brain 
injury? Dialog Clin Neurosci . 2011;13(3):352–359. 140. NINDS Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med . 1995;333:1581–1587. 141. Cocho D, Belvis R, Marti-Fabregas J et al. Reasons for exclusion from thrombolytic 
therapy following acute ischemic stroke. Neurology. 2005;64:719–720. 142. Katzan IL, Furlan AJ, Lloyd LE et al. Use of tissue-type plasminogen activator for acute 
ischemic stroke: The Cleveland area experience. JAMA . 2000;283:1151–1158. 143. Macciocchi SN, Diamond PT, Alves WM, Mertz T. Ischemic stroke: Relation of age, 
lesion location, and initial neurologic deficit to functional outcome. Arch Phys Med 
Rehabil. 1998;79:1255–1257. 144. Be yth RJ, Shorr RI. Epidemiology of adverse drug reactions in the elderly by drug 
class. Drugs Aging . 1999;14:231–239. 145. Dirnagl U, Iadecola C, Mosk owitz MA. Pathobiology of ischaemic stroke: An inte -
grated view. Trends Neurosci . 1999;22:391–397. 146. Mehta SL, Manhas N, Rahubir R. Molecular tar gets in cerebral ischemia for developing 
novel therapeutics. Brain Res Rev . 2007;54:34–66. 147. Fisher M, Bastan B. Identifying and utilizing the ischemic penumbra. Neurology. September 25, 2012;79(13 Suppl 1):S79–S85. 148. Heiss WD. The ischemic penumbra: How does tissue injury evolve? Ann NY Acad Sci . September 2012;1268:26–34. 149.  de la Torre JC, Surgeon JW. Dexamethasone and DMSO in experimental transorbital 
cerebral infarction. Stroke. November–December, 1976;7(6):577–583. 150.  de la Torre JC, Kawanaga HM, Hill PK, Crockard HA, Surgeon JW, Mullan S. 
Experimental therapy after middle cerebral artery occlusion in monkeys. Surg Forum . 1975;26:489–492. 151.  de la Torre JC, Kawanaga HM, Hill PK, Crockard HA, Surgeon JW, Mullan S. 
Experimental therapy after middle cerebral artery occlusion in monkeys. Surg Forum . 1975;26:489–492. 152. Kaakinen T, Heikkinen J, Dahlbacka S, Alaoja H. Fructose-1,6-bisphosphate supports 
cerebral energy metabolism in pigs after ischemic brain injury caused by experimental 
particle embolization. Heart Surg Forum . 2006;9(6):E828–E835. 153. F arias LA, Willis M, Gregory GA. Effects of fructose-1,6-diphosphate, glucose, and 
saline on cardiac resuscitation. Anesthesiology . December 1986;65(6):595–601. 154. Mark ov AK, Brumley MA, Figueroa A, Skelton TN, Lehan PH. Hemodynamic effects 
of fructose 1,6-diphosphate in patients with normal and impaired left ventricular func -
tion. Am Heart J . May 1997;133(5):541–549. 155. Gilboe DD, Kintner D, Fitzpatrick JH, Emoto SE, Bazan NG. Treatment of post-isch -
emic brain with a free radical scavenger and a platelet activating factor antagonist: Recovery of metabolism and function. In Pharmacology of Cerebral Ischemia , eds. H. Oberpichler, J. Kriegistein. Wissenschaftliche-Verlag, Stuttgart, Germany, 1990; pp. 399–407. 156. Phillis JW , Estevez AY . Protective effects of the free radical scavengers, dimethyl sulf -
oxide and ethanol, in cerebral ischemia in gerbils. Neurosci Lett . 1998;244:109–111. 157. Shimizu S, Simon RP , Graham SH. Dimethyl sulfoxide treatment reduces infarction vol -
ume after permanent focal cerebral ischemia in rats. Neurosci Lett . 1997;239:125–127. 158. Bruck R, Aeed H, Shirin H. The hydroxyl radical scavengers dimethyl sulfoxide and 
dimethyl urea protect rats against thioacetamide-induced fulminant hepatic failure. J Hepatol . 1999;31:27–38. 159. Dujo vny M, Rozario R, Kossovsky N, Diaz FG, Segal R. Antiplatelet effect of dimethyl 
sulfoxide, barbiturates, and methyl prednisolone. Ann NY Acad Sci. 1983;411:234–244.239 DMSO in Clinical Neuroprotection
 160. Asmis L, Tanner FC, Sudano I, Lüscher TF, Camici GG. DMSO inhibits human platelet 
activation through cyclooxygenase-1 inhibition. A novel agent for drug eluting stents? Biochem Biophys Res Commun. January 22, 2010;391(4):1629–1633. 161. Lim R, Mullan S. Enhancement of resistance of glial cells by dimeth yl sulfoxide against 
sonic disruption. Ann NY Acad Sci . January 27, 1975;243:358–361. 162. L yman GH, Papahadjopoulos D, Preisler HD. Phospholipid membrane stabilization by 
dimethylsulfoxide and other inducers of Friend leukemic cell differentiation. Biochim 
Biophys Acta . October 19, 1976;448(3):460–473. 163. P amphilon D, Mijovic A. Storage of hemopoietic stem cells. Asian J Transfus Sci . July 
2007;1(2):71–76. 164.  de la Torre JC, Fortin T, Park GA, Pappas BA. Brain blood flow restoration ‘rescues’ 
chronically damaged rat CA1 neurons. Brain Res . September 24, 1993;623(1):6–15. 165. Mark ov AK. Hemodynamics and metabolic effects of fructose 1,6-diphosphate 
in ischemia and shock: Experimental and clinical observations. Ann Emerg Med . 1986;15:1470–1477. 166. Ramos RC, de Meis L. Glucose 6-phosphate and fructose 1,6-diphosphate used as ATP-
generating systems by cerebellum Ca2+-transport ATPase. J Neurochem . 1999;72:81–86. 167. Espanol MT, Litt L, Hasegawa K. Fructose 1,6-diphosphate preserves ATP but not 
intracellular pH during hypoxia in respiring neonatal rat brain slices. Anesthesiology . 1998;88:461–472. 168.  de la Torre JC, Nelson NB, Sutherland RJ, Pappas BA. Reversal of ischemic-induced 
chronic memory dysfunction in aging rats with a free radical scavenger–glycolytic intermediate combination. Brain Res . 1998;779:285–288. 169.  de la Torre JC. Treatment of head injury in mice using a fructose 1,6-diphosphate-
dimethyl sulfoxide combination. Neurosurgery . 1995;37:273–279. 170. Karaça M, Kiliç E, Yazici B, Demir S, de la Torre JC. Ischemic stroke in elderly patients 
treated with a free radical scavenger-glycolytic intermediate solution: A preliminary pilot trial. Neurol Res . 2002;24(1):73–80. 171. T azaki Y , Sakai F, Otomo E. Treatment of acute cerebral infarction with a choline precur -
sor in a multi-center, double blind placebo controlled study. Stroke. 1988;19:211–216.ISBN: 978-1-4987-1467-9
978149871467990000K25303
Dimethyl Sulfoxide  
(DMSO) in Trauma  
and Disease
STANLEY W. JACOB
JACK C. DE LA TORRE
JACOB • DE LA TORRE
CHEMISTRY
First isolated as a chemical compound by a Russian chemist in 1866,  
dimethyl sulfoxide (DMSO) proved to be a near-perfect solvent for  
decades before its remarkable biological and medical activities were  
discovered. DMSO is one of the most prodigious agents ever to come  
out of the world of drug development. Its wide range of biological actions 
involving plants, animals, and humans has led to the publication of tens  
of thousands of articles in the scientific literature. Dimethyl Sulfoxide (DMSO) in Trauma and Disease examines the major 
clinical uses of DMSO in humans as supported by basic evidence derived from experiments in animals, including its effects in disorders such as osteoarthritis, interstitial cystitis, gastrointestinal inflammatory changes, scleroderma, respiratory distress, myasthenia gravis, cardiac disease, traumatic brain injury, and Alzheimer’s disease. The effects of DMSO on pain, cancer, stroke, and spinal cord injury are 
also discussed. The book explores how its chemical structure is able  
to react and deactivate toxic molecules generated by DNA damage, free radical formation, inflammation, oxidation, and infection. For the first time, the collective data on the biological, chemical, and medical actions of DMSO are presented and analyzed from the published scientific literature. Clearly written, the book incorporates easy-to-understand scientific  
descriptions that appeal both to health care professionals and the  
millions of people worldwide who have used DMSO for an assortment of 
ailments as a prescriptive or off-label medication.Dimethyl Sulfoxide  
(DMSO) in Trauma  
and Disease
K25303_Cover_PubGr.indd   All Pages 2/11/15   2:38 PM
Dimethyl_Sulfoxide_(DMSO)_in_Trauma_and_Disease_[2015].txt
Summarize the following text section accurately and concisely. Maintain specific details and numerical information, and use anti-repetition mechanisms:

        Bro wn FD, Johns LM, Mullan S. Dimethyl sulfoxide in experimental brain injury, with 
comparison to mannitol. J Neurosurg. July 1980;53(1):58–62. 78. Bro wn FD, Johns L, Mullan S. Dimethyl sulfoxide therapy following penetrating brain 
injury. Ann NY Acad Sci. 1983;411:245–252. 79. Carlson KK. (ed. ) AACN Advanced Critical Care Nursing. Elsevier Saunders, St Louis, 
MO, 2009; p. 554. 80. Campbell WW. DeJong’s the Neurologic Examination, 6th edn. Lippincott Williams & 
Wilkins, Philadelphia, PA, 2005. 81. W aller FT, Tanabe CT, Paxton HD. Treatment of elevated intracranial pressure with 
dimethyl sulfoxide.
A Russian chemist
Who first isolated dimethyl sulfoxide (DMSO) in 1866?
The major clinical uses of DMSO in humans and its effects in various disorders
What is the primary focus of the book "Dimethyl Sulfoxide (DMSO) in Trauma and Disease"?
By deactivating them
What is one of the ways DMSO reacts with toxic molecules?
It covers the biological, chemical, and medical actions of DMSO, analyzing collective data from the published scientific literature
What is the scope of the book "Dimethyl Sulfoxide (DMSO) in Trauma and Disease"?
To provide easy-to-understand scientific descriptions for both healthcare professionals and individuals who have used DMSO as a prescriptive or off-label medication
What is the purpose of the book "Dimethyl Sulfoxide (DMSO) in Trauma and Disease"?